PTGS2 and malignant colon neoplasm: However, if use of COX-2 inhibitors were to exert a confounding effect on the observed COX-2 genotype/colon cancer association, our inability to control for such confounding is likely to lead to an underestimation, rather than an overestimation, of the risk associated with the putative high-activity genotype.